移植前MRD阴性及年龄<40岁预测CAR-T桥接单倍体HSCT后R/R B-ALL长期生存优势:6年多中心回顾性研究
该多中心回顾性研究长期随访122例抗CD19 CAR-T后达MRD阴性完全缓解的复发/难治B-ALL患者,中位随访72.9个月。桥接单倍体HSCT组较未移植组5年LFS(50.5% vs 25.7%)和OS(53.5% vs 25.6%)均显著提高,移植前MRD阳性是LFS、OS更差及累积复发率更高的独立危险因素。
要点
- CAR-T后达MRD阴性CR的R/R B-ALL患者,桥接单倍体HSCT较未移植显著改善5年LFS和OS。
- 移植前MRD阳性与更差LFS、OS及更高累积复发率独立相关。
- 感染是可能降低长期生存获益的重要并发症。
核心结论
- CAR-T后达CR的R/R B-ALL患者,移植前MRD阴性的单倍体HSCT与更好的长期生存相关。
- 移植前MRD阳性是LFS、OS更差及累积复发率更高的独立不良因素。
研究设计与样本
- 多中心回顾性研究,延伸随访此前报告的122例抗CD19 CAR-T后达MRD阴性CR的R/R B-ALL患者。
- 非移植组67例,后续单倍体HSCT移植组55例,中位随访72.9个月。
主要发现
- 移植组较非移植组5年LFS更高(50.5% vs 25.7%;p<0.001)。
- 移植组较非移植组5年OS更高(53.5% vs 25.6%;p<0.001)。
- MRD-组较MRD+组5年CIR更低(20.8% vs 50.0%;p=0.014)。
- MRD-组与MRD+组5年LFS分别为59.4%和26.7%(p=0.003)。
- MRD-组与MRD+组5年OS分别为62.0%和30.5%(p=0.006)。
关键数值与推荐
- 移植前MRD阳性与更差LFS、OS及更高CIR独立相关(多因素分析)。
- MRD-组5年CIR 20.8%,MRD+组50.0%(p=0.014)。
- MRD-组5年LFS 59.4%,MRD+组26.7%(p=0.003)。
- MRD-组5年OS 62.0%,MRD+组30.5%(p=0.006)。
临床怎么用
- 对CAR-T后达CR的R/R B-ALL患者,可考虑桥接单倍体HSCT以改善长期生存。
- 移植前应评估MRD状态,MRD阴性者长期生存获益更明显。
- 需关注感染等并发症对长期生存获益的影响。
局限性
- 为回顾性研究,非移植组与移植组间可能存在选择偏倚。
- 样本量有限(共122例),结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sequential allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a critical approach to enhance the efficacy of chimeric antigen receptor T cell (CAR-T) therapy for relapsed/refractory acute lymphoblastic leukemia (R/R ALL). The long-term survival rates following allo-HSCT after CAR-T cell therapy remain controversial. We previously reported the results of 122 patients with R/R B-ALL who achieved minimal residual disease negative (MRD-) complete remission (CR) after anti-CD19 CAR-T, including 67 patients without subsequent transplantation (non-transplant group) and 55 patients with subsequent haplo-HSCT (transplant group). Here, we present the extended follow-up of this cohort, with a median of 72.9 months. Compared with the non-transplant group, transplantation recipients had a higher 5-year LFS (50.5% vs. 25.7%; p < 0.001) and OS (53.5% vs. 25.6%; p < 0.001). Multivariable analysis identified MRD positivity at transplantation as an independent factor associated with worse LFS, OS, and a higher cumulative incidence rate of relapse (CIR). MRD-negative patients before transplant (MRD- group) had a lower 5-year CIR compared to MRD-positive patients (MRD+ group) (20.8% vs. 50.0%; p = 0.014). The 5-year LFS rates in the MRD+ and MRD- groups were 26.7% and 59.4%, respectively (p = 0.003). The 5-year OS of the MRD- group was higher than that of the MRD+ group (62.0% vs. 30.5%; p = 0.006). For patients who achieve CR after CAR-T therapy, haplo-HSCT with pre-transplant MRD negativity was associated with better long-term survival. However, infections emerged as a significant complication that may reduce the long-term survival benefits. Trial Registration: ClinicalTrials.gov identifier: ChiCTR1900023957.
引用
- Zhao H, Lin Z, Zheng H, et al. Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-Up. Am J Hematol. 2026. PMID: 42130055. doi:10.1002/ajh.70361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。